

# Keith C Ferdinand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8778724/publications.pdf>

Version: 2024-02-01

128  
papers

10,286  
citations

76326

40  
h-index

33894

99  
g-index

130  
all docs

130  
docs citations

130  
times ranked

11521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension, 2022, 79, 338-348.	2.7	6
2	Cardiovascular Disparities Up South: The Intersection of Geography, Social Determinants, and Race. Mayo Clinic Proceedings, 2022, 97, 7-9.	3.0	1
3	Practical, Evidence-Based Approaches to Nutritional Modifications to Reduce Atherosclerotic Cardiovascular Disease: An American Society For Preventive Cardiology Clinical Practice Statement. American Journal of Preventive Cardiology, 2022, 10, 100323.	3.0	27
4	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 10, 100335.	3.0	58
5	Heart Failure Hospitalizations and Risk Factors among the Multi-Ethnic Population from a Middle Income Country: The Suriname Heart Failure Studies. Journal of the National Medical Association, 2021, 113, 177-186.	0.8	2
6	Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. Journal of the American Heart Association, 2021, 10, e016839.	3.7	14
7	Cardiovascular Disease in Minorities: Unique Considerations: Hypertension in African and Hispanic Americans. Contemporary Cardiology, 2021, , 159-166.	0.1	0
8	Overview and Perspectives: Cardiovascular Disease in Racial/Ethnic Minorities in the Era of COVID-19. Contemporary Cardiology, 2021, , 1-11.	0.1	0
9	Dietary Approaches to Hypertension: Dietary Sodium and the DASH Diet for Cardiovascular Health. Contemporary Cardiology, 2021, , 61-72.	0.1	0
10	Working Agenda for Black Mothers. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007643.	2.2	34
11	Ten things to know about ten cardiovascular disease risk factors. American Journal of Preventive Cardiology, 2021, 5, 100149.	3.0	87
12	Global interventions in hypertension: new and emerging concepts. Current Opinion in Cardiology, 2021, 36, 436-443.	1.8	6
13	Will the 2021 USPSTF Hypertension Screening Recommendation Decrease or Worsen Racial/Ethnic Disparities in Blood Pressure Control?. JAMA Network Open, 2021, 4, e213718.	5.9	11
14	COVID-19 Mitigation: Individual Freedom Should Not Impede Public Health. American Journal of Public Health, 2021, 111, 592-593.	2.7	1
15	Management of Women With Acquired Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum. Journal of the American College of Cardiology, 2021, 77, 1799-1812.	2.8	33
16	Overcoming Barriers to COVID-19 Vaccination in African Americans: The Need for Cultural Humility. American Journal of Public Health, 2021, 111, 586-588.	2.7	23
17	Physical Activity. Mayo Clinic Proceedings, 2021, 96, 844-846.	3.0	0
18	Are SGLT2 Inhibitors New Hypertension Drugs?. Circulation, 2021, 143, 1750-1753.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Response to the letter to the editor by Silverman-Lloyd et al. entitled: "Race is not a risk factor: Reframing discourse on racial health inequities in CVD prevention". American Journal of Preventive Cardiology, 2021, 6, 100188.	3.0	1
20	HDL-C for Atherosclerotic Risk Assessment: Is it Time to Move on?. American Journal of the Medical Sciences, 2021, 362, 433-434.	1.1	0
21	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheterization and Cardiovascular Interventions, 2021, 98, 416-426.	1.7	21
22	Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. American Journal of Preventive Cardiology, 2021, 8, 100250.	3.0	51
23	Disparities in the COVID-19 pandemic: A clarion call for preventive cardiology. American Journal of Preventive Cardiology, 2021, 8, 100283.	3.0	4
24	Racial/Ethnic Considerations in the Prevention of Cardiovascular Disease. Contemporary Cardiology, 2021, , 463-487.	0.1	0
25	Race, Ethnicity, Hypertension, and Heart Disease. Journal of the American College of Cardiology, 2021, 78, 2460-2470.	2.8	36
26	The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension. Progress in Cardiovascular Diseases, 2020, 63, 64-73.	3.1	11
27	Heart failure with preserved ejection fraction: Similarities and differences between women and men. International Journal of Cardiology, 2020, 304, 101-108.	1.7	18
28	Hypertension 2020 update: A view from the Crescent City and beyond. Progress in Cardiovascular Diseases, 2020, 63, 1.	3.1	6
29	Hypertension in African Americans: Advances in community outreach and public health approaches. Progress in Cardiovascular Diseases, 2020, 63, 40-45.	3.1	48
30	Update on hypertension in African-Americans. Progress in Cardiovascular Diseases, 2020, 63, 33-39.	3.1	42
31	Racial disparity in atherosclerotic cardiovascular disease in hospitalized patients with diabetes 2005-2015: Potential warning signs for future U.S. public health. American Journal of Preventive Cardiology, 2020, 4, 100095.	3.0	5
32	State-of-the-Art review: Hypertension practice guidelines in the era of COVID-19. American Journal of Preventive Cardiology, 2020, 2, 100038.	3.0	15
33	The COVID-19 and Influenza "Twindemic": Barriers to Influenza Vaccination and Potential Acceptance of SARS-CoV2 Vaccination in African Americans. Journal of the National Medical Association, 2020, 112, 681-687.	0.8	38
34	Understanding African American COVID-19 Severity and Mortality: Is Obesity the Key?. Obesity, 2020, 28, 1793-1794.	3.0	4
35	Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease. Case Reports in Ophthalmological Medicine, 2020, 2020, 1-4.	0.5	1
36	Uncontrolled hypertension in sub-Saharan Africa: Now is the time to address a looming crisis. Journal of Clinical Hypertension, 2020, 22, 2111-2113.	2.0	15

#	ARTICLE	IF	CITATIONS
37	COVID-19 and Katrina: recalcitrant racial disparities. <i>European Heart Journal</i> , 2020, 41, 3390-3393.	2.2	8
38	Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis. <i>Journal of Medical Virology</i> , 2020, 92, 2473-2488.	5.0	83
39	Contemporary and Future Concepts on Hypertension in African Americans: COVID-19 and Beyond. <i>Journal of the National Medical Association</i> , 2020, 112, 315-323.	0.8	13
40	Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 249-262.	3.1	41
41	African-American COVID-19 Mortality. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2746-2748.	2.8	70
42	Sociodemographic Determinants of Life's Simple 7: Implications for Achieving Cardiovascular Health and Health Equity Goals. <i>Ethnicity and Disease</i> , 2020, 30, 637-650.	2.3	25
43	Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry research-practice-project from the diabetes collaborative registry. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 393-396.	4.4	2
44	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , 2019, 13, 735-743.	1.5	1
45	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. <i>Journal of Clinical Lipidology</i> , 2019, 13, 586-593.e5.	1.5	11
46	Nocturnal Hypertension and Nondipping Blood Pressure: Nature or Nurture?. <i>American Journal of Hypertension</i> , 2019, 32, 720-722.	2.0	0
47	Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. <i>Circulation</i> , 2019, 140, 138-146.	1.6	52
48	Primordial Prevention of Cardiovascular Disease in Childhood. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2022-2024.	2.8	4
49	Improved pathways to hypertension control and elimination of disparities: Are we there yet?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 499-501.	2.0	0
50	Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension. <i>Circulation</i> , 2019, 139, 2098-2109.	1.6	73
51	Uncontrolled Hypertension in Black Men. <i>Circulation</i> , 2019, 139, 20-23.	1.6	8
52	Community Outreach to African-Americans: Implementations for Controlling Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 33.	3.5	11
53	Hypertension Across a Woman's Life Cycle. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1797-1813.	2.8	159
54	Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2018, 34, 361-367.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Novel Interventions in Addressing Racial Disparities in Blood Pressure Control. <i>Circulation</i> , 2018, 138, 339-341.	1.6	5
56	Socioeconomic Status and Cardiovascular Outcomes. <i>Circulation</i> , 2018, 137, 2166-2178.	1.6	737
57	Disparities in hypertension and cardiovascular disease in African Americans: Is the answer in the gut microbiota?. <i>International Journal of Cardiology</i> , 2018, 271, 340-342.	1.7	5
58	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2018, 122, 1496-1505.	1.6	6
59	The role of racial/ethnic factors in global clinical trials. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 829-832.	3.1	7
60	Improved identification of secondary hypertension: use of a systematic protocol. <i>Annals of Translational Medicine</i> , 2018, 6, 293-293.	1.7	5
61	Hypertension and cardiovascular disease in the sub-Saharan African context. <i>Annals of Translational Medicine</i> , 2018, 6, 297-297.	1.7	11
62	Global perspectives on cardiometabolic risk and cardiovascular disease: from basic science to bedside. <i>Annals of Translational Medicine</i> , 2018, 6, 290-290.	1.7	7
63	Current concepts in the management of stable ischemic heart disease and acute coronary syndrome in patients with hemophilia. <i>Annals of Translational Medicine</i> , 2018, 6, 299-299.	1.7	11
64	Improving Medication Adherence in Cardiometabolic Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 437-451.	2.8	118
65	Management of Essential Hypertension. <i>Cardiology Clinics</i> , 2017, 35, 231-246.	2.2	48
66	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3009-3010.	2.8	0
67	Disparities in hypertension and cardiovascular disease in blacks: The critical role of medication adherence. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1015-1024.	2.0	127
68	Disparate Cardiovascular Disease Rates in African Americans: The Role of Stress Related to Self-Reported Racial Discrimination. <i>Mayo Clinic Proceedings</i> , 2017, 92, 689-692.	3.0	14
69	Opportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline-recommended statin therapy. <i>Journal of Clinical Hypertension</i> , 2017, 19, 850-860.	2.0	1
70	Quality and Equitable Health Care Gaps for Women. <i>Journal of the American College of Cardiology</i> , 2017, 70, 373-388.	2.8	86
71	Zika virus pandemic—analysis of Facebook as a social media health information platform. <i>American Journal of Infection Control</i> , 2017, 45, 301-302.	2.3	298
72	Food Deserts. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	4

#	ARTICLE	IF	CITATIONS
73	Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?. <i>Annals of Translational Medicine</i> , 2017, 5, 476-476.	1.7	4
74	Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 421-435.	5.3	45
75	Revealing Masked Hypertension in People of African Ancestry: We Need to Do Better. <i>Journal of Clinical Hypertension</i> , 2016, 18, 393-395.	2.0	1
76	2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	29
77	Research Needs to Improve Hypertension Treatment and Control in African Americans. <i>Hypertension</i> , 2016, 68, 1066-1072.	2.7	78
78	Women, Hypertension, and the Systolic Blood Pressure Intervention Trial. <i>American Journal of Medicine</i> , 2016, 129, 1030-1036.	1.5	50
79	Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. <i>Cardiovascular Diabetology</i> , 2016, 15, 38.	6.8	58
80	Cardiovascular risk reduction in African Americans: Current concepts and controversies. <i>Global Cardiology Science &amp; Practice</i> , 2016, 2016, e201602.	0.4	7
81	Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure. <i>World Journal of Cardiology</i> , 2016, 8, 401.	1.5	6
82	Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 563-572.	2.6	5
83	Clinical Use of Pulse Wave Analysis: Proceedings From a Symposium Sponsored by North American Artery. <i>Journal of Clinical Hypertension</i> , 2015, 17, 503-513.	2.0	41
84	Race/Ethnicity in Atrial Fibrillation Stroke: Epidemiology and Pharmacotherapy. <i>Journal of the National Medical Association</i> , 2015, 107, 59-67.	0.8	1
85	Recognition and Management of Hypertension in Older Persons: Focus on African Americans. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2130-2138.	2.6	13
86	Hypertension in Minority Populations: New Guidelines and Emerging Concepts. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 145-153.	1.4	26
87	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	1.5	430
88	Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002232.	3.9	18
89	PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 295-308.	2.6	18
90	A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk. <i>Current Cardiology Reports</i> , 2015, 17, 38.	2.9	11

#	ARTICLE	IF	CITATIONS
91	The Role of Hypertension in Race-Ethnic Disparities in Cardiovascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	2.0	42
92	Understanding the Importance of Race/Ethnicity in the Care of the Hypertensive Patient. <i>Current Hypertension Reports</i> , 2015, 17, 15.	3.5	17
93	Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 913-923.	1.9	51
94	Emergence of Nonobstructive Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1918-1933.	2.8	257
95	Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: The Atherosclerosis Risk in Communities Study. <i>American Heart Journal</i> , 2015, 169, 155-161.e5.	2.7	48
96	Hypertension in the United States, 1999 to 2012. <i>Circulation</i> , 2014, 130, 1692-1699.	1.6	176
97	2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations. <i>Journal of the American College of Cardiology</i> , 2014, 64, 394-402.	2.8	79
98	Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2014, 64, 731-737.	2.7	111
99	Cardiorenal Metabolic Syndrome and Cardiometabolic Risks in Minority Populations. <i>CardioRenal Medicine</i> , 2014, 4, 1-11.	1.9	34
100	Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents. <i>Current Hypertension Reports</i> , 2014, 16, 455.	3.5	6
101	A Review of the Efficacy and Tolerability of Combination Amlodipine/Valsartan in Non-White Patients with Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 301-313.	2.2	11
102	Obesity and hypertension: It's about more than the numbers. <i>Obesity</i> , 2013, 21, 657-658.	3.0	0
103	Improving Approaches to Hypertension Treatment in African Americans: Lessons Learned From the Jackson Heart Study. <i>Journal of Clinical Hypertension</i> , 2013, 15, 362-364.	2.0	3
104	Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 219-227.	2.3	6
105	Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy. <i>CardioRenal Medicine</i> , 2012, 2, 256-267.	1.9	1
106	Improved Understanding and Innovative Approaches for an Aging Dilemma: Resistant Hypertension in Women with Existing Vascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 450-458.	2.0	1
107	Hypertension in the US Black Population: Risk Factors, Complications, and Potential Impact of Central Aortic Pressure on Effective Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 157-165.	2.6	25
108	Community-Based Approaches to Prevention and Management of Hypertension and Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2012, 14, 336-343.	2.0	48

#	ARTICLE	IF	CITATIONS
109	The Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes (credo). Journal of the American College of Cardiology, 2011, 57, 245-252.	2.8	82
110	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension, 2011, 5, 259-352.	2.3	125
111	Peripheral and Central Blood Pressure Responses of Combination Aliskiren/Hydrochlorothiazide and Amlodipine Monotherapy in African American Patients With Stage 2 Hypertension: The ATLAAS Trial. Journal of Clinical Hypertension, 2011, 13, 366-375.	2.0	20
112	A Compendium of Antihypertensive Therapy. Journal of Clinical Hypertension, 2011, 13, 636-638.	2.0	3
113	Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?. Current Atherosclerosis Reports, 2011, 13, 64-72.	4.8	5
114	Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008. Circulation, 2011, 124, 1046-1058.	1.6	519
115	Progression Is Accelerated From Prehypertension to Hypertension in Blacks. Hypertension, 2011, 58, 579-587.	2.7	104
116	Management of High Blood Pressure in Blacks. Hypertension, 2010, 56, 780-800.	2.7	398
117	Achieving treatment goals in low-risk, asymptomatic patients. Journal of the American Osteopathic Association, The, 2010, 110, S7-13.	1.7	0
118	Nebivolol in High-Risk, Obese African Americans With Stage 1 Hypertension: Effects on Blood Pressure, Vascular Compliance, and Endothelial Function. Journal of Clinical Hypertension, 2009, 11, 720-725.	2.0	15
119	Fixed-Dose Isosorbide Dinitrate-Hydralazine: Race-Based Cardiovascular Medicine Benefit or Mirage?. Journal of Law, Medicine and Ethics, 2008, 36, 458-463.	0.9	4
120	Resistant Hypertension: Diagnosis, Evaluation, and Treatment. Hypertension, 2008, 51, 1403-1419.	2.7	1,333
121	Race-based therapy for hypertension: possible benefits and potential pitfalls. Expert Review of Cardiovascular Therapy, 2008, 6, 1357-1366.	1.5	31
122	Resistant Hypertension: Diagnosis, Evaluation, and Treatment. Circulation, 2008, 117, e510-26.	1.6	1,243
123	The Management of Hypertension in African Americans. Critical Pathways in Cardiology, 2007, 6, 67-71.	0.5	79
124	Barbershops as Hypertension Detection, Referral, and Follow-Up Centers for Black Men. Hypertension, 2007, 49, 1040-1046.	2.7	106
125	Hypertension in Minority Populations. Journal of Clinical Hypertension, 2006, 8, 365-368.	2.0	18
126	Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine, 2004, 351, 2049-2057.	27.0	1,605



#	ARTICLE	IF	CITATIONS
127	The Metabolic Syndrome in African Americans: a review. <i>Ethnicity and Disease</i> , 2003, 13, 414-28.	2.3	66
128	Lessons Learned From the Healthy Heart Community Prevention Project in Reaching the African American Population. <i>Journal of Health Care for the Poor and Underserved</i> , 1997, 8, 366-371.	0.8	58